TABLE 1.
Clinical and demographic parameters of the study sample based on olanzapine dose
| Total sample | Low‐dose group (≤10 mg/day) | High‐dose group (>10 mg/day) | p‐value | |
|---|---|---|---|---|
| N | 392 | 297 | 95 | |
| Age, median (IQR), years | 38.0 (26.0–53.3) | 38.0 (26.0–54.0) | 37.0 (27.0–51.0) | 0.64 |
| Men, n (%) | 208 (53.1) | 149 (50.2) | 59 (62.1) | 0.04 |
| Follow‐up duration, median (IQR), days | 40.0 (20.7–112.2) | 36.0 (18.0–101.0) | 47.0 (28.0–137.0) | 0.01 |
| Olanzapine dose, median (IQR), mg/d | 10.0 (5.0–10.0) | 10.0 (5.0–10.0) | 20.0 (15.0–20.0) | |
| Smoking, n (%) | 212 (54.1) | 143 (48.1) | 69 (72.6) | <0.001 |
| Main diagnosis (%) a | 0.80 | |||
| Schizophrenia spectrum disorders (F20–29) | 211 (53.8) | 151 (50.8) | 60 (63.2) | |
| Mood disorders (F30–39) | 104 (26.5) | 82 (27.6) | 22 (23.2) | |
| Other | 67 (17.1) | 56 (18.9) | 11 (11.6) | |
| Missing | 10 (2.6) | 8 (2.7) | 2 (2.1) | |
| Baseline metabolic parameters | ||||
| Weight, median (IQR) kg | ♂ 74.0 (65.0–82.0) | ♂ 72.4 (65.0–81.0) | ♂ 74.7 (69.7–83.7) | ♂ 0.04 |
| ♀ 59.0 (50.7–71.2) | ♀ 58.1 (50.7–70.2) | ♀ 61.5 (52.0–75.2) | ♀ 0.35 | |
| BMI, median (IQR) kg/m2 | n = 327, 22.7 (20.2–26.2) | n = 260, 22.6 (20.1–26.1) | n = 67, 22.9 (21.1–26.5) | 0.24 |
| Obesity (>30 kg/m2), n/total (%) | 36/327 (11.0) | 27/260 (10.4) | 9/67 (13.4) | 0.51 |
| Hypertension, n/total (%) | 34/70 (48.6) | 27/60 (45.0) | 7/10 (70.0) | 0.18 |
| Raised fasting plasma glucose, n/total (%) | 55/252 (21.8) | 40/197 (20.3) | 15/55 (27.3) | 0.27 |
| Fasting hypertriglyceridaemia, n/total (%) | 54/223 (24.2) | 43/173 (24.9) | 11/50 (22.0) | 0.85 |
| HDL hypocholesterolaemia, n/total (%) | 83/261 (31.8) | 61/197 (31.0) | 22/64 (34.4) | 0.64 |
| Total hypercholesterolaemia, n/total (%) | 114/264 (43.1) | 87/199 (43.7) | 27/65 (41.5) | 0.77 |
| Metabolic syndrome IDF, n/total (%) | 15/323 (4.6) | 10/256 (3.9) | 5/67 (7.5) | 0.21 |
| Co‐medication at baseline b | ||||
| Second antipsychotic | 74/386 (19.2) | 62/294 (21.1) | 12/92 (13.0) | 0.10 |
| Third antipsychotic | 32/386 (8.3) | 19/294 (6.5) | 13/92 (14.1) | 0.03 |
| Antidepressant | 65/392 (16.6) | 47/297 (15.8) | 18/95 (18.9) | 0.53 |
| Benzodiazepine | 288/392 (73.5) | 209/297 (70.4) | 79/95 (83.2) | 0.02 |
| Hypertensive drug | 32/392 (8.2) | 28/297 (9.4) | 4/95 (4.2) | 0.13 |
| Antidiabetic drug | 6/392 (1.5) | 5/297 (1.9) | 1/95 (1.0) | 1.0 |
| Lipid‐lowering drug | 16/392 (4.1) | 13/297 (4.4) | 3/95 (3.1) | 0.77 |
Note: Significant p‐values are indicated in bold.
Abbreviations: BMI, body mass index; HDL, high‐density lipoprotein; IDF, International Diabetes Federation; IQR, interquartile range.
a
Based on international Classification of Diseases (ICD‐10).
b
List of co‐medication detailed in Table S2.